Aquestive Therapeutics is trading 9.3% up at $4.63 in pre-market sessions, following an SEC filing on July 9, 2026, for the registration of 230,271 warrant shares for resale. - These warrants are issuable upon exercise of warrants connected to a Tranche A Term Loan, which forms part of the company's capital-raising initiatives. - The company continues to advance Anaphylm towards a Q3 2026 NDA resubmission, pending FDA feedback on human factors and pharmacokinetic studies.